Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival
- PMID: 16204074
- DOI: 10.1158/0008-5472.CAN-05-0885
Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival
Abstract
Tumor production of vascular endothelial cell growth factor (VEGF)-C is associated with tumor lymphangiogenesis and lymph node metastasis. In this study, we examined the effects of small interfering RNA (siRNA)-mediated inhibition of VEGF-C on murine mammary tumor growth, metastasis, and survival. The mRNA and protein expression of VEGF-C in murine mammary tumor cells stably transfected with a VEGF-C siRNA vector were significantly lower compared with VEGF-C-control vector-transfected cells. Cl66-siVEGFC tumors had lower levels of lymphangiogenesis and lymph node and spontaneous lung metastasis than Cl66-control tumors. However, we did not observe significant differences in primary tumor growth and experimental lung metastasis between mice injected with Cl66-siVEGFC and Cl66-control cells. In addition, mice bearing Cl66-siVEGFC tumors lived significantly longer than mice bearing Cl66-control tumors. Furthermore, our data suggest that inhibition of VEGF-C modulates immune cell infiltration and their function, which might be critical in tumor immunity. In summary, our data show that inhibition of VEGF-C expression using siRNA-mediated gene silencing vectors reduces lymphangiogenesis and lymph node and spontaneous lung metastasis, and enhances survival.
Similar articles
-
Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model.Cancer Gene Ther. 2008 Dec;15(12):776-86. doi: 10.1038/cgt.2008.43. Epub 2008 Jul 25. Cancer Gene Ther. 2008. PMID: 18654613
-
Vector-based RNA interference against vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of colorectal cancer in vivo in mice.Chin Med J (Engl). 2008 Mar 5;121(5):439-44. Chin Med J (Engl). 2008. PMID: 18364118
-
Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma.Anat Rec (Hoboken). 2009 May;292(5):633-9. doi: 10.1002/ar.20893. Anat Rec (Hoboken). 2009. PMID: 19382240
-
Molecular control of lymphatic metastasis.Ann N Y Acad Sci. 2008;1131:225-34. doi: 10.1196/annals.1413.020. Ann N Y Acad Sci. 2008. PMID: 18519975 Review.
-
Lymphangiogenesis and tumor metastasis.Cell Tissue Res. 2003 Oct;314(1):167-77. doi: 10.1007/s00441-003-0748-7. Epub 2003 Jul 18. Cell Tissue Res. 2003. PMID: 12883995 Review.
Cited by
-
Lymphatic vessel: origin, heterogeneity, biological functions, and therapeutic targets.Signal Transduct Target Ther. 2024 Jan 3;9(1):9. doi: 10.1038/s41392-023-01723-x. Signal Transduct Target Ther. 2024. PMID: 38172098 Free PMC article. Review.
-
Heterogeneity of tertiary lymphoid structures in cancer.Front Immunol. 2023 Dec 4;14:1286850. doi: 10.3389/fimmu.2023.1286850. eCollection 2023. Front Immunol. 2023. PMID: 38111571 Free PMC article. Review.
-
Vascular endothelial growth factor-C and its receptor-3 signaling in tumorigenesis.3 Biotech. 2023 Oct;13(10):326. doi: 10.1007/s13205-023-03719-4. Epub 2023 Sep 1. 3 Biotech. 2023. PMID: 37663750 Review.
-
Advancements in Cancer Immunotherapies.Vaccines (Basel). 2022 Dec 27;11(1):59. doi: 10.3390/vaccines11010059. Vaccines (Basel). 2022. PMID: 36679904 Free PMC article. Review.
-
Advances in Drugs Targeting Lymphangiogenesis for Preventing Tumor Progression and Metastasis.Front Oncol. 2022 Jan 6;11:783309. doi: 10.3389/fonc.2021.783309. eCollection 2021. Front Oncol. 2022. PMID: 35087755 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
